Nurix Therapeutics (NASDAQ:NRIX) PT Raised to $25.00

Nurix Therapeutics (NASDAQ:NRIX) had its target price raised by investment analysts at Robert W. Baird from $24.00 to $25.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Robert W. Baird’s target price suggests a potential upside of 49.34% from the company’s current price.

NRIX has been the subject of several other reports. Morgan Stanley upped their price objective on Nurix Therapeutics from $9.00 to $10.00 and gave the stock an “equal weight” rating in a research note on Monday, February 26th. Royal Bank of Canada reduced their price objective on Nurix Therapeutics from $24.00 to $22.00 and set an “outperform” rating for the company in a research note on Friday, February 16th. Needham & Company LLC restated a “buy” rating and issued a $31.00 price objective on shares of Nurix Therapeutics in a research note on Tuesday. HC Wainwright reduced their price objective on Nurix Therapeutics from $35.00 to $19.00 and set a “buy” rating for the company in a research note on Tuesday, February 20th. Finally, Wells Fargo & Company reduced their price objective on Nurix Therapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a research note on Friday, February 16th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, Nurix Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $21.33.

Nurix Therapeutics Trading Down 2.7 %

Shares of NRIX opened at $16.74 on Thursday. The firm has a fifty day simple moving average of $12.64 and a two-hundred day simple moving average of $9.26. Nurix Therapeutics has a 1-year low of $4.22 and a 1-year high of $18.12.

Nurix Therapeutics (NASDAQ:NRIX) last announced its earnings results on Thursday, February 15th. The company reported ($0.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.26). The company had revenue of $15.16 million for the quarter, compared to analysts’ expectations of $30.66 million. Nurix Therapeutics had a negative net margin of 178.93% and a negative return on equity of 67.08%. As a group, analysts forecast that Nurix Therapeutics will post -3.26 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Nurix Therapeutics news, CFO Houte Hans Van sold 6,812 shares of the stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $10.02, for a total transaction of $68,256.24. Following the completion of the transaction, the chief financial officer now owns 68,333 shares of the company’s stock, valued at approximately $684,696.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last quarter, insiders sold 10,817 shares of company stock worth $100,256. Corporate insiders own 7.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. boosted its holdings in shares of Nurix Therapeutics by 48.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 568,576 shares of the company’s stock valued at $4,469,000 after purchasing an additional 184,617 shares during the last quarter. Kennedy Capital Management LLC lifted its holdings in shares of Nurix Therapeutics by 192.7% in the 3rd quarter. Kennedy Capital Management LLC now owns 163,623 shares of the company’s stock valued at $1,286,000 after acquiring an additional 107,719 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Nurix Therapeutics by 351.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,611 shares of the company’s stock valued at $58,000 after acquiring an additional 4,367 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Nurix Therapeutics by 40.9% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 183,923 shares of the company’s stock valued at $1,446,000 after acquiring an additional 53,429 shares during the last quarter. Finally, ARK Investment Management LLC lifted its holdings in shares of Nurix Therapeutics by 23.2% in the 4th quarter. ARK Investment Management LLC now owns 3,194,999 shares of the company’s stock valued at $32,972,000 after acquiring an additional 601,952 shares during the last quarter.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.